Consolidation of Platelet Aggregates by Fibrin Despite Heparin Anticoagulation
Laurerz Wurzinger,P. Blasberg,H. Schmid-schönbein
DOI: https://doi.org/10.1055/s-0038-1653444
1981-05-23
Thrombosis and Haemostasis
Abstract:Dear Sir, it is a well-known and often regretted fact that heparin given as antithrombotic drug to prevent thrombosis in arteries and during the use of artificial organs is not able to suppress thrombus formation reliably. This occurs despite the fact that in vitro coagulability is grossly reduced, as measured, for example, by activated clotting time. White bodies as they originate in artificial organs after full heparinization, contain large amounts of fibrin. We have made an observation, which, in our opinion, gives some explanation to the discrepancy between reduced overall clottability and local thrombus formation. We looked at platelet aggregates (PA) formed in the rheonggregometer (1) upon addition of large doses of ADP (5—10 pMol/L) to platelet rich plasma (PRP), prepared from whole blood, anticoagulated with 5 units heparin per ml. When looking at macroscopically visible aggregates (ca. 0.5-2 mm in diameter) under the phase contrast microscope we observed a peculiar phenomenon: between 5 to 10 min after the aggregate had been removed from the aggregometer, a fibrin network started to form in niches and lacunae of the aggregate. This happened very rarely at convex parts indicating the involvement of a diffusible substance, released from the aggregate. Proof that the observed net consists of fibrin was obtained by staining the aggregates with fluorescent antibodies against human fibrinogen (Behringwerke, Marburg, West Germany). By fluorescence microscopy we could visualize a fluorescent network within the aggregate. These networks proved to be resistant towards 5 molar urea. This finding suggests that despite the presence of heparin in a concentration of ca. 9-10 U/ml (in PRP prepared from whole blood, anticoagulated with 5 U/ml) thrombin had acted upon fibrinogen. Further evidence for this notion could be obtained using a thrombin sensitive chromogenic substrate (Chromozym TH, Boehringer, Mannheim, West Germany). Using a micro scope photometer, the cleavage of the chromogenic group was detected within 30 pm distance from the surface of the aggregate, whereas 200 pm away from the aggregate no thrombin activity could be detected, indicating a complete suppression of the enzyme by heparin. It was impossible to suppress this phenomenon of fibrin formation in aggregates, formed in heparinized PRP, by heparin in concentrations as high as 50 units per ml of whole blood. On the other hand when using clinically relevant heparin concentra tions of 0.5-1 U/ml of whole blood, fibrin was found already 30 sec after removal of the aggregate from the aggregometer, which had been operated for 2 min to allow an aggregate to form. Release of heparin neutralizing platelet proteins, e.g. platelet factor 4 (PF 4) into the plasma gaps within the aggregate and the microenvironment on the aggregate surface, could locally neut ralize the anticoagulant activity of heparin. In experiments with fibrin formation P-thromboglobulin and PF 4 release between 1 and 5 digram, and 0.4 and 2 pgram respectively, per ml super natant were measured by radioimmunoassays. Such quantities of these proteins have the capacity to neutralize approximately 0.04 units of heparin (2). It seems conceivable that heparin neutrali zing potency of this order of magnitude acting on the limited plasma volume in the aggregate is sufficient to antagonize heparin effects. The various procoagulant activities of platelets made available by the ADP stimulus and/or aggregation become effective and finally prothrombin is converted to thrombin, which in turn stimulates release reaction and leads to the observed fibrin formation. From our observations it is clear that the degree of anticoagu lation by heparin, as monitored by macroscopic coagulation assays allows no conclusion about the prevention of microscopic coagulation processes within or near aggregates. In other words we find that heparin is not able to prevent the transformation of a platelet aggregate into a white thrombus, once the aggregate has reached a critical size, which remains to be determined more precisely yet. A white thrombus, however, has a much greater mechanical stability than an aggregate, and thus constitutes quite a different impact for the circulation.